Dr. Cross is a researcher at the Medical University of Vienna. Recently, she has made the case that the reason people who eat soy products have lower rates of cancer is because one of the components of soy, genistein, blocks the enzyme that degrades vitamin D and thus raises tissue levels of activated vitamin D. She makes the case that cancer could not only be prevented, but possibly treated, not only by taking vitamin D, but by manipulating the enzymes that metabolize (build up) and catabolize (break down) vitamin D. It’s important to lay persons and non-medical professionals because the substances necessary to do all this (vitamin D and genistein) are available without a prescription. I should add that Dr. Cross does not recommend lay people do this on their own, she is making the case for further research. However, if you are fighting a serious cancer, the relative risk of taking 10,000 units of vitamin D and 1,000 mg of genistein every day is quite small compared to your impending death. 19
With our impressive results, our Transplant Program at Stony Brook University Hospital, a part of Stony Brook Medicine, is a leader in offering a new anti rejection protocol with the ability in almost all patients to avoid the use of steriods. The goal of immunosuppression following kidney transplantation is to provide safe and effective prevention of rejection of the kidney while minimizing the complications and side effects. Prednisone has long been a cornerstone of immunosuppression therapy for over 40 years. However, many patients suffer side effects of Prednisone including weight gain, high blood pressure, diabetes, bone disease, hyperlipidemia, cataracts as well as cosmetic problems. At SBUH we have had excellent results using a protocol that avoids oral prednisone altogether after kidney transplantation. Our results have been presented nationally using less than normal maintenance immunosuppression and no oral prednisone. Patients receive at the time of transplant, a single dose of Campath-1H (a monoclonal antibody) plus three doses of intravenous Methylprednisone. Patients are discharged home on two oral anti-rejection medications and no prednisone. Results to date have been excellent with low rates of rejection and infection with close careful follow-up. We are excited to be able to offer this option to patients both after a living donor as well as deceased donor kidney transplants.